引用本文: | 粟艳婷,蔡宝国,张健.大麻二酚新剂型的研究进展[J].中国现代应用药学,2022,39(6):840-847. |
| SU Yanting,CAI Baoguo,ZHANG Jian.Research Progress of Novel Formulations of Cannabidiol[J].Chin J Mod Appl Pharm(中国现代应用药学),2022,39(6):840-847. |
|
摘要: |
大麻二酚(cannabidiol,CBD)是从植物大麻中提取的非成瘾性成分,近几年来许多研究表明CBD具有多种药理作用和高安全性,主要包括抗癫痫、抗惊厥、治疗疼痛、抗炎及神经保护特性等。由于CBD的内在性质具有亲脂性高、水溶性差及易经过首过代谢的特点,使其口服生物利用度低,导致CBD的临床用药效率低,不利于其作为常规的制剂使用。本文主要对近几年来提高CBD的溶解性及生物利用度的新型制剂研究进行综述,对透皮传递系统、透黏膜传递系统、自乳化传递系统、新型固体制剂等新技术提高CBD的溶解性及生物利用度试验研究进行阐述并作出展望。 |
关键词: 大麻二酚 新型制剂 水溶性 生物利用度 |
DOI:10.13748/j.cnki.issn1007-7693.2022.06.022 |
分类号:R94 |
基金项目: |
|
Research Progress of Novel Formulations of Cannabidiol |
SU Yanting, CAI Baoguo, ZHANG Jian
|
Department of Fragrance and Cosmetics, Shanghai Institute of Technology, Shanghai 200418, China
|
Abstract: |
Cannabidiol(CBD) is a non-addictive ingredient extracted from the plant cannabis. In recent years, many studies have shown that CBD has a variety of pharmacological effects and high safety, including anti-epileptic, anti-convulsant, treatment pain, anti-inflammatory and neuroprotective properties. Due to the inherent properties of CBD with high lipophilicity, low water solubility and easy first-pass metabolism, it leads to low oral bioavailability and reduces the clinical efficiency of CBD, which is not conducive to its use as a conventional preparation. This article mainly reviews the research on novel formulations that improve the solubility and bioavailability of CBD in recent years, and expounds the experimental research on new technologies such as transdermal delivery systems, transmucosal delivery systems, self-emulsifying delivery systems and new solid formulations to improve the solubility and bioavailability of CBD, and research tendency and developing prospects were also outlined. |
Key words: cannabidiol novel formulation solubility bioavailability |